AR080972A1 - PRODUCTION OF VIRAL COMPONENTS - Google Patents
PRODUCTION OF VIRAL COMPONENTSInfo
- Publication number
- AR080972A1 AR080972A1 ARP110101441A AR080972A1 AR 080972 A1 AR080972 A1 AR 080972A1 AR P110101441 A ARP110101441 A AR P110101441A AR 080972 A1 AR080972 A1 AR 080972A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- cell culture
- culture
- incorporation
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Uso de dicho método en la produccion de la vacuna contra la gripe. En forma adicional, provee a un proceso para evaluar si la incorporacion de un numero muy bajo de partículas de virus infecciosos por célula (MOI) de una cepa de virus pre-seleccionado a una composicion de cultivo celular para la propagacion de partículas virales conduce a un aumento de la produccion de partículas virales y/o partículas virales procesadas. Reivindicacion 1: Un método para la propagacion del virus de la gripe que comprende hemaglutinina inmunogénica (HA), en donde las células se cultivan en cultivo celular en un primer paso y en donde con posterioridad las partículas infecciosas de la gripe se agregan al cultivo celular en un segundo paso, en donde el medio de cultivo usado para el cultivo de las células se reemplaza antes de o durante el paso de incorporacion del virus por medio de cultivo con una osmolaridad de por lo menos 80% cuando se compara con la osmolaridad del medio de cultivo usado previamente para el cultivo de las células y que no tiene una cantidad significativamente más baja, con preferencia no menos de 50%, de la cantidad total de proteínas, factores de crecimiento y/o sales inorgánicas cuando se compara con el medio de cultivo usado previamente para el cultivo de las células, en donde la cantidad de células en el cultivo celular en el momento de la incorporacion del virus es por lo menos 0,5x106 células/ml, en donde dentro del lapso de 12 a 36 horas después de la incorporacion del virus la densidad de células vivas no es menor que 40% de la densidad celular en el momento de la incorporacion del virus, en donde el numero total de partículas virales infecciosas por células agregadas durante el paso de incorporacion del virus (Multiplicidad de la infeccion, MOl) es menos de 10-5.Use of this method in the production of the flu vaccine. Additionally, it provides a process to assess whether the incorporation of a very low number of infectious virus particles per cell (MOI) of a pre-selected virus strain into a cell culture composition for the propagation of viral particles leads to an increase in the production of viral particles and / or processed viral particles. Claim 1: A method for the spread of the influenza virus comprising immunogenic hemagglutinin (HA), wherein the cells are cultured in cell culture in a first step and wherein subsequently the infectious particles of the flu are added to the cell culture. in a second step, where the culture medium used for cell culture is replaced before or during the step of incorporating the virus through culture with an osmolarity of at least 80% when compared to the osmolarity of the culture medium previously used for cell culture and that does not have a significantly lower amount, preferably not less than 50%, of the total amount of protein, growth factors and / or inorganic salts when compared to the medium of culture previously used for cell culture, where the amount of cells in the cell culture at the time of incorporation of the virus is at least 0.5x10 6 cells / ml, where within 12 to 36 hours after virus incorporation the density of living cells is not less than 40% of the cell density at the time of virus incorporation, where the total number of infectious viral particles by aggregated cells during the virus incorporation step (Multiplicity of infection, MOl) is less than 10-5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10161256 | 2010-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR080972A1 true AR080972A1 (en) | 2012-05-23 |
Family
ID=42269600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101441 AR080972A1 (en) | 2010-04-28 | 2011-04-27 | PRODUCTION OF VIRAL COMPONENTS |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR080972A1 (en) |
TW (1) | TW201202425A (en) |
WO (1) | WO2011134660A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824536A (en) | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
AU694592B2 (en) | 1994-11-16 | 1998-07-23 | St. Jude Children's Research Hospital | Novel replication process |
WO2006071563A2 (en) | 2004-12-23 | 2006-07-06 | Medimmune Vaccines, Inc. | Non-tumorigenic mdck cell line for propagating viruses |
US7883844B2 (en) | 2006-05-11 | 2011-02-08 | Juridical Foundation The Chemosero-Therapeutic Research Institute | Method for propagating influenza virus |
KR20140075022A (en) * | 2006-09-15 | 2014-06-18 | 메디뮨 엘엘씨 | Mdck cell lines supporting viral growth to high titers and bioreactor process using the same |
EP1911836A1 (en) | 2006-10-12 | 2008-04-16 | AVIR Green Hills Biotechnology Trading GmbH | Medium supplement for virus production |
CN102216450B (en) * | 2008-09-24 | 2014-05-14 | 米迪缪尼有限公司 | Methods for cultivating cells, propagating and purifying viruses |
-
2011
- 2011-04-27 AR ARP110101441 patent/AR080972A1/en unknown
- 2011-04-27 TW TW100114740A patent/TW201202425A/en unknown
- 2011-04-28 WO PCT/EP2011/002135 patent/WO2011134660A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
TW201202425A (en) | 2012-01-16 |
WO2011134660A1 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2555959T3 (en) | Method of manufacturing viral vaccines in stem cell lines derived from airborne embryos in suspension | |
CN101668539B (en) | Duck embryonic derived stem cell lines for the production of viral vaccines | |
ES2536745T3 (en) | Methods of production of influenza vaccine compositions | |
AR065076A1 (en) | VACCINE AGAINST PAPILOMAVIRUS | |
CL2016000240A1 (en) | Immunogenic composition of fish reovirus (prv) comprising prv nucleic acid; polypeptide; attenuated or inactivated prv virus, use of the immunogenic composition that is used to treat conditions of prv infection in an animal. | |
AR094389A1 (en) | USE OF iNOS INHIBITORS TO INCREASE THE VIVIC PERFORMANCE IN CROPS | |
EA200801221A1 (en) | VIRAL VACCINES OBTAINED FROM CELLS WITH LOW LEVELS OF RESIDUAL CELL DNA | |
BRPI0518568A2 (en) | Method for producing a replicative influenza virus particle without the use of helper virus, replicative influenza virus particle, Cell, composition, use of a composition, Method for generating immunological protection against infection of an individual with an influenza virus, , Nucleic acid | |
BRPI0922867B8 (en) | respiratory syncytial virus (rsv) fusion glycoprotein (f), isolated nucleic acid, host cell, vaccine composition and purified micelle | |
ECSP066916A (en) | VACCINE AGAINST ESTREPTOCOCO AGALACTIAE | |
NZ611531A (en) | Bovine viral diarrhea virus type 1b vaccine compositions and methods | |
AR079710A1 (en) | PROCESS FOR THE ADHERENT CELL CULTURE | |
CO7461133A2 (en) | Parvovirus 5a pig, methods of use and vaccine | |
UA110505C2 (en) | Immunogenic composition containing bordetella bronchiseptica | |
CL2013002723A1 (en) | Method of production of a virus-like particle (vlp) of salmonid alphavirus (sav) in insect cells. | |
AR082281A1 (en) | PARAPOXVIRUS VECTORS | |
AR094810A1 (en) | PARVOVIRUS PORCINO 5B, METHODS OF USE AND VACCINE | |
CL2012003219A1 (en) | Recombinant parapoxvirus comprising a parapoxvirus and heterologous DNA derived from a rabies virus; preparation process of said parapoxvirus; immunogenic composition; use of the composition to induce immune response against rabies virus in an animal. | |
AR080972A1 (en) | PRODUCTION OF VIRAL COMPONENTS | |
CN103209707A (en) | Viral vaccine and process for preparing the same | |
AR085800A1 (en) | EQUINAL RINITIS VACCINE | |
Stittelaar et al. | Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine | |
WO2023018817A8 (en) | Truncated influenza neuraminidase and methods of using the same | |
MX341622B (en) | An aqueous composition comprising a biological antigen and an acrylic acid polymer. | |
AR079970A1 (en) | HIGH PERFORMANCE VIRUSES OF THE YELLOW FEVER VIRUS WITH INCREASED PROPAGATION IN THE CELLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |